Patents by Inventor Zhiwei Yin

Zhiwei Yin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic alkene derivatives as HIV attachment inhibitors
    Patent number: 9655888
    Abstract: Compounds of Formula (I), including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: and wherein Z is: are useful as HIV attachment inhibitors.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: May 23, 2017
    Assignee: ViiV Healthcare UK (No.5) Limited
    Inventors: Tao Wang, John F. Kadow, Nicholas A. Meanwell, Zhongxing Zhang, Zhiwei Yin, Edward H. Ruediger, Clint A. James, Daniel H. Deon
  • Macrocyclic compounds as HCV entry inhibitors
    Patent number: 9624245
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: April 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Zhiwei Yin, Li-Qiang Sun, Eric Mull, Qian Zhao, Paul Michael Scola
  • 2-keto amide derivatives as HIV attachment inhibitors
    Patent number: 9586957
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: I useful as HIV attachment inhibitors.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: March 7, 2017
    Assignee: ViiV Healthcare UK (No.5) Limited
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, John A. Bender, Barry L. Johnson, John F. Kadow, Nicholas A. Meanwell
  • PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20170057977
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: February 13, 2015
    Publication date: March 2, 2017
    Inventors: John F. KADOW, B. Narasimhulu NAIDU, Manoj PATEL, Kevin PEESE, Tao WANG, Zhiwei YIN, Zhongxing ZHANG
  • SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS
    Publication number: 20160207918
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Application
    Filed: March 16, 2016
    Publication date: July 21, 2016
    Inventors: Tao Wang, Zhongxing Zhang, Nicholas A. Meanwell, John F. Kadow, Zhiwei Yin, Qiufen May Xue, Alicia Regueiro-Ren, John D. Matiskella, Yasutsugu Ueda
  • PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
    Publication number: 20160152615
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 2, 2016
    Inventors: TAO WANG, Zhongxing Zhang, Nicholas A. Meanwell, John F. Kadow, Zhiwei Yin, Qiufen May Xue, Alicia Regueiro-Ren, John D. Matiskella, Yasutsugu Ueda
  • SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
    Publication number: 20160075703
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Application
    Filed: October 8, 2015
    Publication date: March 17, 2016
    Inventors: TAO WANG, Zhongxing Zhang, Nicholas A. Meanwell, John F. Kadow, Zhiwei Yin, Qiufen May Xue, Alicia Regueiro-Ren, John D. Matiskella, Yasutsugu Ueda
  • 2-KETO AMIDE DERIVATIVES AS HIV ATTACHMENT INHIBITORS
    Publication number: 20160052924
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: I useful as HIV attachment inhibitors.
    Type: Application
    Filed: March 25, 2014
    Publication date: February 25, 2016
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Madison, John A. Bender, Barry L. Johnson, Jhon F. Kadow, Nicholas A. Meanwell
  • PIPERAZINE AND HOMOPIPERAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS
    Publication number: 20160052923
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are useful as HIV attachment inhibitors.
    Type: Application
    Filed: March 25, 2014
    Publication date: February 25, 2016
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, Barry L. Johnson, John F. Kadow, Nicholas A. Meanwell
  • Cyano containing azabenzofuran compounds for the treatment of hepatitis C
    Patent number: 9249152
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: February 2, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Kyle J. Eastman, Zhongxing Zhang, Kyle E. Parcella, Zhiwei Yin, John F. Kadow
  • COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20160024111
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: March 5, 2014
    Publication date: January 28, 2016
    Inventors: Tao WANG, Zhiwei YIN, Paul Michael SCOLA
  • MACROCYCLIC COMPOUNDS AS HCV ENTRY INHIBITORS
    Publication number: 20150368267
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: February 4, 2014
    Publication date: December 24, 2015
    Inventors: Tao WANG, Zhongxing ZHANG, Zhiwei YIN, Li-Qiang SUN, Eric MULL, Qian ZHAO, Paul Michael SCOLA
  • PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
    Publication number: 20150329543
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Application
    Filed: May 29, 2015
    Publication date: November 19, 2015
    Inventors: Tao Wang, Zhongxing Zhang, Nicholas A. Meanwell, John F. Kadow, Zhiwei Yin, Qiufen May Xue, Alicia Regueiro-Ren, John D. Matiskella, Yasutsugu Ueda
  • GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20150320757
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: January 23, 2014
    Publication date: November 12, 2015
    Inventors: TAO WANG, Zhongxing Zhang, Ying Han, Zhiwei Yin, Paul Michael Scola
  • AMMONIUM DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20150322085
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: January 23, 2014
    Publication date: November 12, 2015
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, Paul Michael Scola
  • Tricyclic amidine derivatives as HIV attachment inhibitors
    Patent number: 9156828
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: (F) wherein A is selected from the group consisting of: (F) and; (F) and wherein Z is: (F) are useful as HIV attachment inhibitors.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: October 13, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Zhiwei Yin, John F. Kadow, Nicholas A. Meanwell
  • CYANO CONTAINING AZABENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20150266886
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Application
    Filed: March 20, 2015
    Publication date: September 24, 2015
    Inventors: Tao Wang, Kyle J. Eastman, Zhongxing Zhang, Kyle E. Parcella, Zhiwei Yin, John F. Kadow
  • SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
    Publication number: 20150259342
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Application
    Filed: May 29, 2015
    Publication date: September 17, 2015
    Inventors: Tao Wang, Zhongxing Zhang, Nicholas A. Meanwell, John F. Kadow, Zhiwei Yin, Qiufen May Xue, Alicia Regueiro-Ren, John D. Matiskella, Yasutsugu Ueda
  • TRICYCLIC AMIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS
    Publication number: 20150210676
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: (F) wherein A is selected from the group consisting of: (F) and; (F) and wherein Z is: (F) are useful as HIV attachment inhibitors.
    Type: Application
    Filed: August 7, 2013
    Publication date: July 30, 2015
    Inventors: Tao Wang, Zhongxing Zhang, Zhiwei Yin, John F. Kadow, Nicholas A. Meanwell
  • TRICYCLIC ALKENE DERIVATIVES AS HIV ATTACHMENT INHIBITORS
    Publication number: 20150190387
    Abstract: Compounds of Formula (I), including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: and wherein Z is: are useful as HIV attachment inhibitors.
    Type: Application
    Filed: August 7, 2013
    Publication date: July 9, 2015
    Inventors: Tao Wang, John F. Kadow, Nicholas A. Meanwell, Zhongxing Zhang, Zhiwei Yin, Edward H. Ruediger, Clint A. James, Daniel H. Deon